Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2004 - ascopubs.org
7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
被引用次数：401 相关文章

[引用][C] Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2004 - cir.nii.ac.jp
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC)
chemotherapy in advanced non-small cell lung cancer (NSCLC) | CiNii Research CiNii 国立 …

[引用][C] Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

U GATZEMEIER - Proc Am Soc Clin Oncol., 2004 - cir.nii.ac.jp
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC)
chemotherapy in advanced non-small cell lung cancer (NSCLC) | CiNii Research CiNii 国立 …